👤 Ben Geoffrey A S

Neurodevelopmental and neurodegenerative diseases involve critical abnormalities in pathogenesis. Even though there exists copious drugs and treatments, still a need for an effective model for absolute replication of disease pathophysiology and therapeutic drug discovery. This comprehensive systematic review amasses methods and approaches for developing neuronal models for neurological diseases using hPSCs/iPSCs. Abundant culturing methods, growth factors, modulators and toxins were utilised to induce the disease and were appraised. Research articles were traced from Google Scholar, PubMed/NIH, and Science Direct. Publications using hPSCs/iPSCs as differentiated neuronal disease models were screened using PRISMA guidelines, with designed inclusion and exclusion criteria. This protocol highlights the procedures for developing 2D and 3D neuronal models derived from hPSCs/iPSCs. 2D neuronal models include NPCs, NSCs, and neural rosettes, neurons, while 3D methods rely on embryoid bodies, neurospheres, spheroids and organoids due to the enhanced differentiation, survival and maturation of hPSCs/iPSCs. These processes include varied factors for culturing. Growth factors like GDNF, BDNF, cAMP, ascorbic acid, TGF-β, and Dual-SMAD inhibition. Post-analytical techniques like MEA, H&E, TEM, microscopy, immunoassays, and electrophysiology ensures the structural and functional endorsements. These models offer researchers a reliable platform to investigate the disease physiopathology and drug design for neurological disorders. Show less

Alzheimer's disease (AD) is moving toward earlier, biology-driven diagnosis, which increases the need for blood-based markers that are reliable, scalable, and interpretable across populations. This review integrates the AT(N) framework with a maturity model for circulating biomarkers. We first describe core and largely validated plasma measures, including LC-MS or automated immunoassay Aβ42/Aβ40 ratios, p tau217 and p tau231, glial fibrillary acidic protein (GFAP), and neurofilament light, and we relate them to recent multi-stakeholder recommendations on analytical performance and regulatory status. We then summarize replicated but context-dependent markers, such as soluble TREM receptors, CHI3L1, and MCP 1, which improve risk stratification when interpreted together with amyloid and tau. A separate section examines emerging readouts that capture central nervous system (CNS) processes indirectly, focusing on neuron-enriched extracellular vesicles (EVs) and EV-carried microRNA panels. These signatures are biologically plausible and often precede symptoms, although current datasets are small, Alzheimer's disease neuroimaging initiative (ADNI)-based, and require standardized pre-analytical handling and external validation before clinical triage can be recommended. We also discuss platform selection, comparing automated electrochemiluminescence (ECL) and single-molecule assays with LC-MS, and outline how composite plasma panels that include APOE genotype can support screen-confirm-monitor workflows in memory clinics. Finally, we propose a tiered implementation path in which genomic risk profiling and blood tests identify candidates for cerebrospinal fluid (CSF) or positron emission tomography (PET) studies. This shows how circulating and multi-omics biomarkers can be layered onto established plasma Amyloid beta (Aβ) and p tau assays to widen the measurable blood space in Alzheimer's disease. Show less

The dysregulation of long-chain noncoding RNAs (lncRNAs) causes several complex human diseases including neurodegenerative disorders across the globe. This study aimed to investigate lncRNA expression profiles of Withania somnifera (WS)-treated human neuroblastoma SK-N-SH cells at different timepoints (3 & 9 h) and concentrations (50 & 100 µg/mL) using RNA sequencing. Differential gene expression analysis showed a total of 4772 differentially expressed lncRNAs, out of which 3971 were upregulated and 801 were downregulated compared to controls. Differential gene expression was observed in dose-dependent (30 upregulated, 25 downregulated, 100 µg/mL 3 h vs. 50 µg/mL 3 h; 36 upregulated, 247 downregulated, 100 µg/mL 9 h vs. 50 µg/mL 9 h) and temporal kinetics (79 upregulated, 64 downregulated, 50 µg/mL 9 h vs. 50 µg/mL 3 h; 22 upregulated, 200 downregulated, 100 µg/mL 9 h vs. 100 µg/mL 3 h). Enrichment analysis showed that modulated lncRNAs were mainly implicated in GPCR ligand binding, HDACs and HATs histones, cellular senescence, cell cycle and post-translational protein modifications. Dysregulated lncRNAs upon WS treatment included BACE1-AS, MALAT1, SNHG1, HOTAIR, MEG3, BDNF-AS, and SHANK2-AS1 which are potential biomarkers in several neurodegenerative diseases. Co-expression analysis revealed that genes such as HMOX1, CHGB, SLC7A11, NOS1, KCNJ and NPY2R may be important in neurodegenerative disorders. Taken together, our results indicated that WS treatment modulated several differentially expressed lncRNAs with putative regulatory potential in various neurodegenerative disorders. To the best of our knowledge, the lncRNA regulome that elicits the health-beneficial effects of WS has not been delineated thus far. Show less

Lipoprotein (a) [Lp(a)] levels are closely related to the development of ischemic heart disease in international studies; however, the impact on the severity of coronary and cardiac involvement in our country has not been described. High levels of Lp(a) are associated with greater involvement of coronary disease and ventricular function compromise. Cross-sectional study among patients with ischemic heart disease admitted to a cardiac intensive care unit after acute coronary syndrome (ACS) or after coronary angioplasty for chronic coronary syndrome. Lipid profile and Lp(a) measurements were performed within the first 24 hours of admission, and echocardiogram with left ventricular ejection fraction (LVEF) measurement was performed within 5 days of admission. The magnitude of coronary disease (number of coronary arteries severely affected) and LVEF were evaluated in patients distributed according to Lp(a) levels considering a cut-off of 30 mg/dL and 50 mg/dL. One hundred and eighteen subjects were recruited, aged 65.9±20.2 years, 74.6% men, and 75% with ACS. Sixty patients (50.8%) were taking statins. Left anterior descending artery involvement was observed in 78.8%, with mean LVEF 49.9±17.5%, LDL 95.6±43.4 mg/dL (LDL >70 mg/dL in 69.4%), non-HDL 120.4±49.1 mg/dL, and Lp(a) 40.5±38.6 mg/dL. Lp(a) levels >30 mg/dL were detected in 42.3% and >50 mg/ dL in 27.9% of subjects. Lp(a) >30 mg/dL was associated with LVEF <40% (OR 2.6, p= 0.02), and values >50 mg/dL were related to LVEF <40% (OR 3.7, p= 0.03) and significant disease of 2 or more coronary arteries (OR 2.4, p= 0.04). Multivariate logistic regression analysis showed that Lp(a) levels >50 mg/dL were related to a higher risk of LVEF <40% (OR 3.8, p<0.01) and multivessel coronary disease (OR 2.8, p= 0.03). In patients with established coronary heart disease, elevated Lp(a) levels are associated with a greater severity of coronary involvement and a lower LVEF. Show less

PROTAC (proteolysis-targeting chimeras) is a rapidly evolving technology to target undruggable targets. The mechanism by which this happens is when a bifunctional molecule binds to a target protein and also brings an E3 ubiquitin ligase in proximity to trigger ubiquitination and degradation of the target protein. Yet, in-silico-driven approaches to design these heterobifunctional molecules that have the desired functional properties to induce proximity between the target protein and E3 ligase remain to be established. In this paper, we present a novel in-silico method for PROTAC design and to demonstrate the validity of our approach, we show that for a BRD4-VHL-PROTAC-mediated ternary complex known in the literature, we are able to reproduce the PROTAC binding mode, the structure of the ternary complex formed therein, and the free energy (Δ Show less

Kisspeptin (encoded by the KISS1 gene in humans) is an excitatory neuromodulatory peptide implicated in multiple homeostatic systems, including anti-oxidation, glucose homeostasis, nutrition, locomotion, etc. Therefore, in the current obesity epidemic, kisspeptin is gaining increasing interest as a research objective. To construct an updated interactome of genetic obesity, including the kisspeptin signal transduction pathway. Kisspeptin and obesity-related genes or gene products were extracted from the biomedical literature, and a network of functional associations was created. The generated network contains 101 nodes corresponding to gene/gene products with known and/or predicted interactions. In this interactome, KISS1 and KISS1R are connected directly to the luteinizing hormone receptor (LHCGR), gonadotropin-releasing hormone receptor (GNRH1), and indirectly, through the latter, to proopiomelanocortin (POMC), glucagon, leptin (LEP), and/or pro-protein convertase subtilisin/kexin-type 1 (PCSK1), all of which are critically implicated in obesity disorders. Our updated obesidome includes kisspeptin and its connections to the genetic obesity signalosome with 12 major hubs: glucagon (GCG), insulin (INS), arginine vasopressin (AVP), G protein subunit beta 1 (GNB1) and proopiomelanocortin (POMC), melanocortin 4 receptor (MC4R), leptin (LEP), gonadotropin-releasing hormone 1 (GNRH1), adrenoceptor beta 2 and 3 (ADRB2-3), glucagon-like peptide 1 receptor (GLP1R), and melanocortin 3 receptor (MC3R) genes were identified as major "hubs" for genetic obesity, providing novel insight into the body's energy homeostasis. Show less

Chronic venous diseases, including varicose veins, are characterized by hemodynamic disturbances due to valve defects, venous insufficiency, and orthostatism. Veins are physiologically low shear stress systems, and how altered hemodynamics drives focal endothelial dysfunction and causes venous remodeling is unknown. Here we demonstrate the occurrence of endothelial to mesenchymal transition (EndMT) in human varicose veins. Moreover, the BMP4-pSMAD5 pathway was robustly upregulated in varicose veins. In vitro flow-based assays using human vein, endothelial cells cultured in microfluidic chambers show that even minimal disturbances in shear stress as may occur in early stages of venous insufficiency induce BMP4-pSMAD5-based phenotype switching. Furthermore, low shear stress at uniform laminar pattern does not induce EndMT in venous endothelial cells. Targeting the BMP4-pSMAD5 pathway with small molecule inhibitor LDN193189 reduced SNAI1/2 expression in venous endothelial cells exposed to disturbed flow. TGFβ inhibitor SB505124 was less efficient in inhibiting EndMT in venous endothelial cells exposed to disturbed flow. We conclude that disturbed shear stress, even in the absence of any oscillatory flow, induces EndMT in varicose veins Show less